Revier Therapeutics raises $6.5M
Revier Therapeutics announced a Seed round of $6.5M on 28 August 2026. The company operates in HealthTech and is based in Germany. It was founded by Eva van Rooij, CEO and Co-founder.
Founder
Eva van Rooij
CEO and Co-founder, Revier Therapeutics
Outreach angles
- -Eva van Rooij is a cardiovascular disease researcher who co-founded Revier Therapeutics to translate her lab's work into new therapies.
- -Van Rooij built the company with scientific co-founder Johannes Backs around their academic research into class IIa HDAC inhibitors.
- -Launched with a 6 million euro seed round led by KHAN Technology Transfer Fund II to develop cardiometabolic disease treatments.
Signals
SeedHealthcareDeep TechRegulated IndustryB2B
Round details
Company: Revier Therapeutics
Domain: revier.bio
Amount: $6.5M
Stage: Seed
Industry: HealthTech
Country: Germany
Announced: 28 August 2026
Other HealthTech raises
Recently funded in Germany